InDex Pharmaceuticals


	News & Events 2013-04-08 InDex Pharmaceuticals reports completion of patient recruitment in Phase III Ulcerative Colitis Study (COLLECT) with Kappaproct. Read more... InDex Pharmaceuticals meddelar slutförandet av patientrekrytering i fas III ulcerös kolit studie (COLLECT) med Kappaproct. Läs mer... 2012-10-24 InDex Pharmaceuticals Granted Japanese Patent for Novel Treatment of Steroid-Resistant Inflammation. Read more... InDex Pharmaceuticals beviljas japanskt patent för ny behandling av steroidresistent inflammation. Läs mer... 2012-08-30 InDex Pharmaceuticals Strengthens IP Position for Kappaproct. Read more... InDex Pharmaceuticals utökar patentportföljen för läkemedelskandidaten Kappaproct. Läs mer... 2012-07-09 InDex publish positive results from Kappaproct Compassionate Use program. Click for article 2012-06-19 Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ulcerative Colitis. Read more... Kappaproct minskar behovet av kirurgiskt ingrepp för patienter med svår ulcerös kolit. Läs mer... 2012-05-29 InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member. Read more... InDex Pharmaceuticals utser Stig Løkke Pedersen Pedersen till styrelseledamot. Läs mer... 2012-04-26 InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant Inflammation. Read more... InDex Pharmaceuticals beviljas amerikanskt patent för ny behandling av steroidresistent inflammation. Läs mer... 2012-04-11 InDex Pharmaceuticals Expands Management Team. Read more... InDex Pharmaceuticals utökar ledningsgruppen. Läs mer... 2012-03-20 InDex Pharmaceuticals develops companion diagnostic test for new ulcerative colitis therapy. Read more... InDex Pharmaceuticals utvecklar companion diagnostics för ny ulcerös kolit behandling. Läs mer... 2012-03-06 InDex Pharmaceuticals Starts Phase III COLLECT Study with Kappaproct®. Read more... InDex Pharmaceuticals startar fas III studien COLLECT för Kappaproct®. Läs mer... 2011-10-24 InDex Pharmaceuticals participates at the UEGW (19th United European Gastroenterology Week) at Stockholmsmässan Oct 24-26. 2011-07-07 InDex Pharmaceuticals names Jesper Wiklund Chief Executive Officer. Read more... 2011-05-17 InDex Pharmaceuticals participates in the Swedish Congress Svenska Gastrodagarna in Umeå May 17-20, 2011. 2011-01-21 InDex Pharmaceuticals completes SEK 75m finance round. Read more... 2010-05-17 Index Pharmaceuticals is present with a booth in the yearly congress Svenska Gatrodagarna in Stockholm 17-20 May, 2010. 2009-12-08 Stockholms läns landsting introduces diagnostic test for patients with inflammatory bowel disease. Read more... 2009-11-11 Patent for the diagnostic test DiBiCol granted in Japan. Read more... 2009-05-18 Based on positive Phase II Results InDex Pharmaceuticals terminates Kappaproct study in advance. Read more... 2009-03-19 Last patient recruited in a Phase II study of Kappaproct. Read more... 2008-11-05 InDex Pharmaceuticals AB has filed five more patents that will further strengthen its extensive portfolio of proprietary intellectual assets. Read more...
InDex Pharmaceuticals AB, Retzius väg 8, 171 77 Stockholm, Phone: +46 8 508 847 30, Fx: +46 8 508 847 39, info@indexpharma.com Copyright © 2012 InDex Pharmaceuticals AB. All Rights Reserved.